Circulate Health’s Plasma Exchange Platform Backed by Landmark Aging Biomarker Study

New updates have been reported about Circulate Health.

Circulate Health’s precision therapeutic plasma exchange (TPE) platform is gaining scientific validation from a large-scale aging biomarker study that positions the company at the center of evidence-based longevity therapeutics. A newly published preprint, integrating immunoglobulin G (IgG) glycome data from 20,405 individuals across 42 studies, identifies IgG glycans as independently predictive of all-cause mortality and shows that Circulate’s TPE protocols can measurably reverse biological age.

The research, led by Professor Gordan Lauc and collaborators from more than 20 institutions, is the first to unify glycan aging, disease risk, mortality, and intervention responsiveness within a single analytic framework. Within this framework, three geroprotective interventions—TPE, hormone replacement therapy, and caloric restriction—were evaluated, with TPE showing the largest per-month reduction in glycan age, underscoring Circulate’s core modality as the most potent intervention among those tested.

The study builds directly on Circulate Health’s previously published single-blind, randomized, placebo-controlled human trial with the Buck Institute, which demonstrated that biweekly TPE combined with intravenous immunoglobulin reduced multi-omics biological age by an average of 2.6 years. The new data extend that evidence base, showing in an independent cohort that monthly TPE sessions reduced glycan age by approximately 0.4 years per month, reinforcing the consistency and magnitude of TPE’s rejuvenation effect. For Circulate, this alignment of multi-omics and glycan-based endpoints strengthens the clinical rationale for its standardized TPE protocols.

Therapeutic plasma exchange has decades of use in autoimmune, neurological, and hematological indications, but its application to healthspan has historically lacked robust, validated aging biomarkers. The new IgG glycome analysis helps close that gap by satisfying the Biomarkers of Aging Consortium’s criteria: mechanistic grounding in inflammation-related hallmarks of aging, predictive power for all-cause mortality, and responsiveness to geroprotective interventions such as TPE. This validation enhances Circulate’s ability to position TPE as an evidence-backed longevity intervention for clinicians, payers, and regulators.

Circulate’s business model relies on delivering standardized, protocol-driven TPE through a growing network of partner longevity clinics in the United States, supported by specialized apheresis nurses and operational infrastructure. The strengthened evidence base may accelerate adoption of Circulate’s services, support premium pricing for high-touch clinical programs, and attract strategic partnerships with longevity clinics and research institutions. As longevity science moves toward more rigorous, outcome-driven interventions, Circulate is positioned as a first mover with randomized human data and now a complementary glycan biomarker framework.

Co-founder Eric Verdin, who also serves as CEO of the Buck Institute for Research on Aging, emphasized that the field is entering a phase where mechanistic insights can be linked to measurable outcomes in patients, highlighting Circulate’s role in that transition. For executives and investors, the combination of large-scale biomarker validation, randomized trial data, and operational readiness suggests a pathway for Circulate to shape standards in clinical longevity, while also creating optionality for future reimbursement discussions and potential expansion into broader preventive or chronic disease markets.